Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 16, 2023

Pembrolizumab vs Ipilimumab for Advanced Melanoma: 7-Year Follow-Up of KEYNOTE-006

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
J. Clin. Oncol 2023 Jun 22;[EPub Ahead of Print], C Robert, MS Carlino, C McNeil, A Ribas, JJ Grob, J Schachter, M Nyakas, D Kee, TM Petrella, A Blaustein, M Lotem, A Arance, AI Daud, O Hamid, J Larkin, J Anderson, C Krepler, D Grebennik, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading